哈三联：2025年前三季度净利润约-2.09亿元

Group 1 - Company Hasi Lian reported a revenue of approximately 581 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 30.75% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 209 million yuan, with a basic earnings per share loss of 0.66 yuan [1] - The current market capitalization of Hasi Lian is 4.5 billion yuan [2] Group 2 - The Chinese innovative drug sector has sold overseas authorizations worth 80 billion US dollars this year [2] - The secondary market for biomedicine is experiencing a boom, while the primary market is facing challenges in fundraising [2]